Table 1 Characterization of loaded and non-loaded nanodevices
From: Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer
Formulation | RH (nm) | PdI | Z-Potential (mV) | EE (%) | LE (%) | Antibody conjugation (%) |
|---|---|---|---|---|---|---|
NP | 113.73±2.40 | 0.110±0.01 | 4.05±0.81 | – | – | – |
NP-Alpelisib | 104.60±1.05 | 0.066±0.02 | 4.57±0.88 | 38.34±5.22 | 4.25±1.20 | – |
NP-DiR | 106.53±1.00 | 0.112±0.03 | 3.94±0.95 | 3.72±0.44 | 0.41±0.04 | – |
ACNP | 129.70±4.30 | 0.190±0.08 | 2.53±0.55 | – | – | 93±1.80 |
ACNP-Alpelisib | 108.80±0.82 | 0.126±0.03 | 9.64±1.18 | 18.47±1.92 | 6.84±0.84 | 85±2.44 |
ACNP-DiR | 131.80±1.31 | 0.162±0.01 | 1.98±0.30 | 2.47±0.22 | 0.39±0.04 | 89±2.30 |